Document is current
Any future updates will be listed below
-
Authors
Oomkens, Dorien https://orcid.org/0009-0007-4197-0950
Mujagic, Zlatan https://orcid.org/0000-0001-5211-0381
de Vries, Annemarie https://orcid.org/0000-0002-3988-9201
van der Meulen-de Jong, Andrea https://orcid.org/0000-0001-9353-5431
Straatmijer, Tessa https://orcid.org/0000-0001-6989-5226
Löwenberg, Mark https://orcid.org/0000-0002-4975-9945
van der Marel, Sander https://orcid.org/0009-0002-7672-2483
West, Rachel https://orcid.org/0000-0003-1914-9393
Bodelier, Alexander https://orcid.org/0000-0002-2329-9995
van Schaik, Fiona https://orcid.org/0009-0003-2451-1809
Visschedijk, Marijn https://orcid.org/0000-0001-7277-7677
Duijvestein, Marjolijn https://orcid.org/0000-0003-4814-9376
,
van Bodegraven, Ad
de Boer, Nanne
Bouma, Gerd
Dijkstra, Gerard
D’Haens, Geert
van Dop, Willemijn
Festen, Noortje
Groenen, Marcel
Horjus, Carmen
Jansen, Jeroen
de Jong, Dirk
Jharap, Bindia
Leemreis, Desiree
Maljaars, Jeroen
Mahmmod, Nofel
Mares, Wout
Mensink, Peter
Nissen, Loes
Oostenbrug, Liekele
Oldenburg, Bas
Pierik, Marieke
Ponsioen, Cyriel
Römkens, Tessa
Russel, Maurice
Smid, Jael
Srivastava, Nidhi
Stokkers, Pieter
Voorneveld, Philip
van der Voorn, Michael
van der Woude, Janneke
Weersma, Rinse
- License Information
-
More Information
Article History
Received: 12 February 2025
Accepted: 8 April 2025
First Online: 16 April 2025
Declarations
:
: DO: none. ZM: reports grants from ZonMw, MLDS, Niels Stensen Fellowship, and Galapagos, and has served as speaker for Galapagos, adviser for Johnson and Johnson, Pfizer, Galapagos, AbbVie and Lilly. ACV: advisory boards for Takeda, Janssen, Bristol Myers Squibb, Abbvie, Pfizer, and Galapagos; research grants from Takeda, Janssen, and Pfizer, outside submitted work. AEvdM: speaker for Galapagos, Janssen-Cilag, Takeda, Tramedico; research grants from Cablon, Galapagos, Nestle, Norgine, and ZonMW. TS: none. ML: Abbvie, Bristol Myers Squibb, Eli Lilly, Galapagos, Janssen-Cilag, Johnson & Johnson, Medtronic, Pfizer, Takeda, Tillotts. Central reader for Alimentiv. Grants received from Galapagos, Pfizer and ZonMW. SvdM: advisory boards for Pfizer, Abbvie, and Janssen, outside submitted work; IBD documentary funded by Takeda; podcast funded by Janssen. RW: advisory board or speaker for Janssen, Abbvie, and Pfizer. AB: advisory board of Takeda, Abbvie, and Janssen, outside submitted work. FvS: adviser and/or speaker for Takeda, Galapagos, Dr. Falk, Lilly and Janssen-Cilag and received an unrestricted grant from Takeda. MCV: speaker fees from Janssen-Cilag, Galapagos, and Ferring B.V. MD: advisory fees from Echo Pharma and Robarts Clinical Trials, Inc.; speaker fees from Janssen, Merck & Co., Inc., Pfizer, Takeda, and Tillotts Pharma; nonfinancial support from Dr. Falk Pharma.
: The study was reviewed and approved by the Committee on Research Involving Human Subjects at the Radboudumc [institutional review board: 4076], and all procedures adhered to the Declaration of Helsinki.
: Informed consent was obtained from all participants in the ICC registry.
